In short
Clinical trials are studying TRONTINEMAB in people with Alzheimer’s disease, including prodromal, mild, and moderate stages. These studies are checking safety, tolerability, and whether TRONTINEMAB may slow disease progression or reduce brain amyloid, a protein linked to Alzheimer’s disease.
Key points
- TRONTINEMAB is being studied in clinical trials for Alzheimer’s disease, including prodromal, mild, and moderate stages. One study is Phase 1 and focuses on safety, tolerability, and brain amyloid changes, while two studies are Phase 3 and look at clinical progression over 72 weeks. The Phase 3 studies include people with early symptomatic Alzheimer’s disease, such as mild cognitive impairment and mild dementia due to AD. The main outcomes include side effects, brain MRI and lab safety checks, amyloid PET scans, and the CDR-SB score. All listed studies are authorised and use placebo comparison in some parts of the research.
Trial overview
TRONTINEMAB is being studied in interventional clinical trials, which means researchers assign study treatment and compare results across groups. The listed trials focus on Alzheimer’s disease, including early and more advanced symptomatic stages.
Three authorised studies are shown in the source data. One is a Phase 1 study with 256 participants, and two are Phase 3 studies with 800 participants each.
Who is being studied
The Phase 1 study includes participants with prodromal or mild to moderate Alzheimer’s disease. Prodromal means an early stage where symptoms are starting, but are still relatively mild.
The two Phase 3 studies include participants with early symptomatic Alzheimer’s disease, described as mild cognitive impairment (MCI) to mild dementia due to AD. MCI means thinking or memory problems that are worse than expected for age, but not yet as severe as dementia.
What the trials measure
The Phase 1 study mainly measures safety and tolerability, which means whether the treatment can be given without major problems and how well participants handle it. It also measures pharmacodynamics, which in this trial means the effect of repeated doses on the body, and brain amyloid load by amyloid PET scan.
The safety checks in the Phase 1 study include adverse events, laboratory tests, vital signs, physical and neurological exams, 12-lead ECG, and brain MRI findings, including vasogenic edema and hemorrhage. These checks help researchers watch for changes in the body and brain during the study.
The Phase 3 studies focus on clinical progression over 72 weeks and compare TRONTINEMAB with placebo. Their main outcome is change from baseline in the Clinical Dementia Rating, Sum of Boxes (CDR-SB), a scale used to track how dementia symptoms change over time.
Trial phases and study design
The Phase 1 study is a multiple ascending dose trial, which means different dose levels are studied step by step to learn more about safety and early effects. It also includes long-term administration in one part of the study.
The Phase 3 studies are larger trials designed to test whether TRONTINEMAB changes disease course compared with placebo. Both are authorised and use placebo comparison, which helps show whether any observed changes are likely due to the study treatment.
Key trial details
Trial 2023-509678-52-00 is titled Brainshuttle AD and studies RO7126209, which the source data links with TRONTINEMAB, in participants with prodromal or mild to moderate Alzheimer’s disease. The primary outcomes are safety events and change in brain amyloid load.
Trial 2024-518006-40-00 studies TRONTINEMAB in early symptomatic Alzheimer’s disease and looks at change in CDR-SB at Week 72 versus placebo. The study includes imaging tracers and placebo as part of the trial design, showing that researchers are comparing brain-related measures and clinical outcomes.
Trial 2024-518008-33-00 is another Phase 3 study in the same early symptomatic population and uses the same main outcome, change in CDR-SB at Week 72. Having two Phase 3 studies suggests a broader effort to confirm results in similar patient groups.
What the endpoints mean
Primary outcome means the main result the researchers are trying to measure. In the Phase 1 study, the main outcomes are safety-related and include brain MRI and amyloid PET results.
In the Phase 3 studies, the main endpoint is the change in CDR-SB from baseline to Week 72. Baseline means the starting point before treatment, and Week 72 means the planned follow-up timepoint after treatment has been given for a long period.
The source data also lists several imaging agents, including Amyvid, VIZAMYL, Neuraceq, and [18F]MK-6240, which are used in the study design for brain imaging measures. These are part of how the trials assess brain changes, not separate treatment goals.